Jean-Charles Soria

Jean-Charles Soria, MD, PhD is Chief Medical Officer of the Investigational Drug Branch and a professor at Gustave Roussy Cancer Campus in Villejuif, France—one of Europe's largest and most prestigious cancer centers. He has been one of the most prominent European phase I trialists of his generation, having led or contributed to first-in-human trials of osimertinib, alectinib, durvalumab, and numerous other oncology agents that subsequently achieved regulatory approval. Dr. Soria built the Drug Development Department (DITEP) at Gustave Roussy into one of the largest early-phase programs in Europe, conducting over 60 concurrent phase I and II trials. He has been a strong proponent of accelerated titration designs and pharmacologically guided dose escalation to improve the efficiency of dose escalation in oncology. His work on molecular predictors of response in phase I—particularly in EGFR-mutant and ALK-rearranged lung cancer—demonstrated the transformative potential of genomic patient selection in first-in-human studies. He co-founded the EORTC Early Clinical Trials Working Group and has contributed extensively to European regulatory science and early-phase trial methodology.